CD15, CD24, and CD29 Define a Surface Biomarker Code for Neural Lineage Differentiation of Stem Cells§

Authors

  • Jan Pruszak,

    Corresponding author
    1. McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, Belmont, Massachusetts, USA
    • McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, 115 Mill Street, Belmont, Massachusetts 02478, USA
    Search for more papers by this author
  • Wesley Ludwig,

    1. McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, Belmont, Massachusetts, USA
    Search for more papers by this author
  • Alexandra Blak,

    1. McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, Belmont, Massachusetts, USA
    Search for more papers by this author
  • Kambiz Alavian,

    1. McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, Belmont, Massachusetts, USA
    Search for more papers by this author
  • Ole Isacson

    Corresponding author
    1. McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, Belmont, Massachusetts, USA
    • McLean Hospital/Harvard Medical School, Center for Neuroregeneration Research, 115 Mill Street, Belmont, Massachusetts 02478, USA
    Search for more papers by this author
    • Telephone: 617-855-3283; Fax: 617-855-3284


  • Author contributions: J.P.: Conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; W.L.: Administrative support, collection and/or assembly of data, data analysis and interpretation; A.B., K.A.: Collection and/or assembly of data; O.I.: Conception and design, grant support, data analysis and interpretation, manuscript writing, final approval of manuscript.

  • First published online in STEM CELLS EXPRESS August 20, 2009.

  • §

    Disclosure of potential conflicts of interest is found at the end of this article.

Abstract

Identification and use of cell surface cluster of differentiation (CD) biomarkers have enabled much scientific and clinical progress. We identify a CD surface antigen code for the neural lineage based on combinatorial flow cytometric analysis of three distinct populations derived from human embryonic stem cells: (1) CD15+/CD29HI/CD24LO surface antigen expression defined neural stem cells; (2) CD15/CD29HI/CD24LO revealed neural crest-like and mesenchymal phenotypes; and (3) CD15/CD29LO/CD24HI selected neuroblasts and neurons. Fluorescence-activated cell sorting (FACS) for the CD15/CD29LO/CD24HI profile reduced proliferative cell types in human embryonic stem cell differentiation. This eliminated tumor formation in vivo, resulting in pure neuronal grafts. In conclusion, combinatorial CD15/CD24/CD29 marker profiles define neural lineage development of neural stem cell, neural crest, and neuronal populations from human stem cells. We believe this set of biomarkers enables analysis and selection of neural cell types for developmental studies and pharmacological and therapeutic applications. STEM CELLS 2009;27:2928–2940

INTRODUCTION

Differentiating human pluripotent stem cells mirror all stages of cell development and lineages [1] and could represent an unlimited source of cells for therapeutic paradigms in regenerative medicine [2, 3]. Mouse and human embryonic stem (ES) cells, induced pluripotent stem (iPS) cells, or nuclear transfer cells have been used experimentally to develop analytical and cell replacement approaches for neurological disorders [4–8]. Functional recovery has been achieved in animal models of disease [7, 9], and clinical data on cell therapy in the nervous system using human fetal material, although controversial [10], has shown proof-of-principle success [11–14]. Pluripotent stem cells, however, carry a risk of uncontrolled growth [15], and after transplantation, tumors of neural and non-neural (teratoma) tissue origin have been observed [7, 9, 16]. The occurrence of tumors in applications of pluripotent stem cell-derivatives mandates precise cell selection steps [17, 18]. Fluorescence-activated cell sorting (FACS) is an approach to eliminate non-neural cells from mixed cell preparations derived from ES cells for in vitro and in vivo studies [15, 19].

Such cell-sorting strategies require novel biomarkers to enable the selection of specific cell populations of potential therapeutic and scientific value for the fields of regenerative medicine and stem cell biology [15, 17, 18]. The combinatorial detection of surface markers by multicolor flow cytometry has been widely applied in the fields of hematology and immunology [20, 21], but has up to now only been marginally exploited in neurobiology [22–25]. A recent surface marker screen yielded an initial documentation of cluster of differentiation (CD) antigens expressed during human ES (hES) neural differentiation [15], but on the whole, the neural lineage remains yet to be defined according to a combinatorial surface antigen code [17].

Previous studies utilized genetic fluorescent markers such as Tau-GFP [26], Synapsin-GFP [15], Pitx3-GFP [27], or dye labeling [28] to isolate mature, differentiated neurons. However, clinical applicability of such cell isolation methods analogous to hematological diagnosis and therapy depends on the usage of surface markers. We and others previously applied FACS methodology optimized for neural cell selection [15] to successfully eliminate tumor-generating proliferative cells from ES cell- [15, 19, 27, 29] as well as iPS-cell-derived [6] neural cell populations. Importantly, FACS is routinely applied in hematological cell transplantation to generate clinical-grade cell preparations of high purity [21]. In addition, there is considerable analytical value in the identification and isolation of multiple neural subsets exclusively by surface antigens: this eliminates the need for a genetic reporter and enables close monitoring of stem cell differentiation using a rapid quantitative readout. In summary, although the technology is feasible and available, it has not been extensively applied due to a lack of a comprehensive combinatorial marker analysis.

Here, our aim was to discover a surface antigen profile of neural lineage differentiation by identifying and characterizing specific neural cell subsets derived from pluripotent stem cells.

MATERIALS AND METHODS

Pluripotent Stem Cell Culture and Differentiation

Work with hES cells was approved by the Partners Embryonic Stem Cell Research Oversight Committee. Undifferentiated human ES cell lines H7 (WA-07, XX, passages 40-65) and H9 (WA-09, XX, passages 35-45) were cultured under growth conditions and passaging techniques previously described [7]. In vitro analysis was done with both hES cell lines, the transplantation assay was done with H9. Undifferentiated hES cell cultures were maintained on mitotically inactivated human fibroblasts (D551; ATCC, Manassas, VA, http://www.atcc.org). Human ES cell neuronal induction and differentiation were achieved, essentially as previously described [7, 15]: a neural induction phase on stromal feeder cells with 300 ng/ml of Noggin was followed by careful manual selection of neural rosettes using microdissection (at 21 div) and subsequent culture on laminin/poly-ornithine substrate with N2-based medium (42 div and beyond) [30]. Mouse ES and induced pluripotent stem (iPS) cell neuronal differentiation was done in a five-stage embryoid body-based protocol as previously described [6, 27, 31]. Cell lines used were as follows: mouse ES cell lines J1 and R1 (both ATCC), Pitx3-GFP (M. Li; see Hedlund et al. [27]); Sox1-GFP (A. Smith; see Chung et al. [19]); the Oct4-selected mouse iPS cell line O9 (R. Jaenisch; see Wernig et al., 2007, 2008 [6, 32]).

Neural Surface Antigen Staining

Cells were harvested and gently dissociated using TrypLE Express (Invitrogen/Gibco, Carlsbad, CA, http://www.invitrogen. com). Cells were filtered through cell strainer caps (35-μm mesh; BD Biosciences, San Diego, http://www.bdbiosciences.com) to obtain a single cell suspension (approximately 106 cells per ml for analysis, 0.5–2 × 107 cells per ml for sorting). Cell viability was routinely determined to be above 90% by trypan blue dye exclusion before use for analysis and sorting experiments. Species-specific antibodies were used whenever available; the CD15 and FORSE-1 antibodies were found to label neuroepithelial cell types on both mouse and human cell sources. For colocalization assays on neural precursors (Fig. 1B), H7 cells were infected at day in vitro (div) 21 with lentivirus containing a Nestin-GFP reporter (Isacson et al., unpublished). FORSE-1, SSEA-1, and SSEA-3 antibodies were obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. Surface antigens were labeled by incubating with the primary antibodies (see supporting information Table 1) for 20 minutes at room temperature, followed by incubation for 20 minutes with the appropriate Alexafluor-488 or Alexafluor-647 fluorescent secondary antibodies. Alternatively, coniugated antibodies were used (BD Pharmingen, San Diego, http://www.bdbiosciences.com). All washing steps were performed in cold phenol-free, Ca2+-free, Mg2+-free Hank's buffered saline solution (Invitrogen/Gibco) containing penicillin-streptomycin (Invitrogen/Gibco), 20 mM D-glucose (Sigma, St. Louis, http://www.sigmaaldrich.com), and 2% fetal bovine serum (HyClone, Logan, UT, http://www.hyclone.com) [15].

Figure 1.

Surface antigen expression profiles of neural cell types. (A) Study design. Screening for surface antigens expressed during neural differentiation of hESC enables the discovery of specific neural cell subsets according to a combination of these markers. These are subsequently selected by FACS for detailed characterization in vitro and in vivo. (B) Genetic fluorescent markers such as Nestin-GFP identify neural precursor cells derived from human ES cells. Cells gated as the Nestin-GFP+ fraction did not express immature stem cell markers such as SSEA-3. Surface antigen expression analysis proved essential to detect the presence of additional distinct cell populations within the neural subset, for example, displaying discrete levels of CD29 (− / LO / HI) and FORSE1 (−/ +) antigen expression. Control gates as indicated were set against corresponding negative controls (<0.5%). (C) Profiling of surface antigens such as carbohydrate epitopes (CD15 [SSEA1; Lewis- X]; FORSE1), beta1-integrin (CD29), and sialoglycoprotein epitopes such as the glycosylphosphatidylinositol-linked heat-stable antigen CD24 [BA-1; small-cell lung carcinoma cluster four antigen; nectadrin] and the immunoglobulin superfamily member CD56 [NCAM] on neurally differentiated human ES cells was obtained by flow cytometric analysis (div 42; three independent experiments). Representative percentages of cells positively stained within the overall live cell population. Abbreviations: ES = embryonic stem; FACS = fluorescence-activated cell sorting; hESC = immature human embryonic stem cells; hES NP = neurally induced hES cells at the neuroepithelial precursor stage (21-39 div); hES ND = hES cells at neuronal differentiation stage (40+ div).

Flow Cytometry and Cell Sorting

The stained cells were analyzed and sorted on a fluorescence-activated cell sorter FACSAria (BD Biosciences) using FACSDiva software (BD Biosciences); data were additionally analyzed using FlowJo software (Tree Star, Ashland, OR, http://www.treestar. com). The fluorochromes were excited with the instrument's standard 488-nm and 633-nm lasers, and green fluorescence was detected using 490 LP and 510/20 filters and far-red fluorescence using 660/20 filters. Fluorescence was determined by analysis and gating against appropriate controls (unstained, secondary antibody-only, GFP-negative cells) at an identical stage of maturity and prepared in parallel. For triple staining, analysis was done in the green, red, and far-red channels. Cell populations of interest were gated to count a minimum of 10,000 live-gate events, excluding doublets, based on forward and side scatter of control samples. All flow cytometric analyses and sorts were repeated at least three times. Gates determining positivity were set so that less than 0.5% of positive events were present when acquiring the corresponding negative control. Gates for “high” (HI) versus “low” (LO) populations were set in comparison to the appropriate non-fluorescent control and adjusted to include visually discernable clusters, if revealed by combinatorial staining. To assure specificity, appropriate separation of sorted fractions was verified visually and by FACS reanalysis of the subsets defined in that manner (>80% enrichment post-sort) as described before [19]. Prior to aseptic sorting, the nozzle, sheath, and sample lines were sterilized with 70% ethanol for 15 minutes, followed by washes with sterile water to remove remaining decontaminant. A 100-μm ceramic nozzle (BD Biosciences), sheath pressure of 20-25 PSI, and an acquisition rate of 1,000-3,000 events per second were used as conditions optimized for neuronal cell sorting (“gentle FACS”) as previously described [15].

Flow Cytometric Analysis of Intracellular Neural Antigens

Staining for intracellular antigens was done using commercially available fixation and buffer solutions IntraCyte fix solution, wash solution, and block reagent (Neuromics, www.neuromics. com). After careful validation and titration, the following antibodies were used at dilutions optimized for flow cytometric analysis: βIII tubulin (TuJ1), doublecortin, TH, MAP2, Pax3 (see supporting information Table 2). It should be noted that different primary antibodies against the intracellular antigens stain with varying levels of background fluorescence, enabling relative comparison between groups, but not an absolute quantitation. For combined surface and intracellular antigen detection, live cells were stained for surface antigens as described above, followed by fixation and permeabilization to stain the intracellular epitopes.

Embryonic Central Nervous System Tissue Dissection and Dissociation

Timed pregnant C57BL/6 mice (Jackson ImmunoResearch, West Grove, PA, http://www.jacksonimmuno.com) were anesthetized with intraperitoneal sodium pentobarbital (300 mg/kg) and decapitated. Primary fore- and midbrain tissue was obtained from E13 mouse embryos (Charles River, Wilmington, MA, http://www.criver.com) using a dissecting microscope. The overlying scalp tissue and the outer meninges were removed entirely to expose forebrain and midbrain tissue, which were dissected as described in detail elsewhere [33]. For isolation of spinal cord tissue, a longitudinal paramedian cut along the dorsal midline was performed, and the spinal cord was isolated using forceps and microscissors. Dissected primary neural tissue was incubated with TrypLE express (Invitrogen/Gibco, Carlsbad, CA), and gently dissociated with fire-polished Pasteur pipettes. For FACS analysis and cell sorting, cells were resuspended in Hank's Buffered Salt Solution (HBSS)-buffered glucose solution, filtered through a 35 μm mesh and brought to a concentration of 0.5–2.0 × 106 cells/ml.

Immunofluorescence, Imaging, and In Vitro Analysis

Indirect immunofluorescence was performed on 4% paraformaldehyde-fixed cell cultures and brain tissue. Fixed cells were incubated in a blocking solution consisting of 10% normal donkey or goat serum (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA) and 0.1% Triton X-100 (Sigma, St Louis) in 0.1 M phosphate-buffered saline (PBS) for 1 h at room temperature. Primary antibodies were diluted in blocking solution and added to the cells. Dilutions of the primary antibodies used were as listed in supporting information Table 2. Antibody concentrations for detection of surface antigens were determined by titration assays using flow cytometric analysis and immunocytochemistry, including staining of viable, attached ES cell and primary neural cultures as previously described [15]. The appropriate fluorescence-labeled secondary antibodies (Alexafluor goat or donkey anti-rabbit, -mouse, or -sheep 488, 594, 647; Molecular Probes, Eugene, OR, http://probes.invitrogen.com; 1:500) were applied for visualization, and nuclei were counterstained with Hoechst 33,342 (Molecular Probes, Invitrogen, Carlsbad, CA; 5 μg/ml). On selected samples, the primary antibody was omitted to verify specificity of staining.

For visual microscopic analysis, quantification was performed by counters blinded to experimental groups on the stained coverslips using an integrated Axioskop-2 microscope (Carl Zeiss, Thornwood, NY, http://www.zeiss.com) and Stereoinvestigator image-capture equipment and software (MicroBrightField, Williston, VT, www.mbfbioscience.com). A contour was drawn around each coverslip to identify the area of interest. A physical dissector probe was utilized, and counting frames were placed in a systematically random manner at ∼100 sites per coverslip. For each experiment, an average of 2,000 cells was scored.

Quantitative RT-PCR Gene Expression Analysis

Total RNA was extracted by using the RNeasy kit and DNase I treatment (Qiagen, Valencia, CA). RNA samples from NS, NC, and ND populations were reverse-transcribed into cDNA using Sensiscript reverse transcriptase (Qiagen, Valencia, CA, http://www1.qiagen.com) and oligo dT as the primer. Polymerase chain reactions (PCRs) were set up in 25 μl reaction volume using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA, http://www.appliedbiosystems.com). Primers for each candidate gene were designed using MacVector 7.0 and used with a final concentration of 250 nM. See supporting information Table 3 for a list of primers used. For each primer pair, duplicates of three independently collected samples were compared to quantify relative gene expression differences between these cells. Beta-actin was used as an internal control gene.

Immunoblotting

Cells and tissue samples were collected from and suspended in lysis buffer containing the following: 50 mM Tris-HCl, 0.15 M NaCl, 0.32 M sucrose, 1.0 mM EDTA, and 1% NP-40. In addition, phosphatase inhibitors I and II (1:100) and protease inhibitors (1:100) were added fresh before cell lysis (P2850, P5276, and P8340, respectively; Sigma). After cell lysis, the homogenate was centrifuged, a portion of the supernatant was reserved for protein determination (BCA Assay; Pierce, Rockford, IL, http://www.piercenet.com), and the remainder was stored at –20°C. Solubilized protein (40 μg) was mixed 1:1 with sample buffer and boiled for 5 minutes. The samples and molecular weight standards were separated using the Criterion precast 4-15% SDS–polyacrylamide gel system (Bio-Rad, Hercules, CA). After electrophoresis, the proteins were electrically transferred to polyvinylidene difluoride membranes at 100 V for 30 minutes. After transfer, blots were incubated in Tris-buffered saline with 0.1% Tween 20 containing 5% BSA. Subsequently, blots were incubated with the TuJ1 primary antibody (1:2000; Covance, Princeton, NJ, http://www.covance.com) at 4°C overnight. Horseradish peroxidase (HRP)-conjugated secondary antibodies were then applied, and immunoreactive bands were visualized with chemiluminescence (GE Healthcare, Little Chalfont, U.K., http://www.gehealthcare. com) and exposed onto film. Immunoblots were then stripped and reprobed for the expression of ß-actin (1:10,000; Abcam, Cambridge, MA, http://www.abcam.com) serving as a loading control. Optical density analysis (NIH Image, http://rsb.info.nih.gov/nih-image/) was used to determine the relative abundance of protein in each sample.

Transplantation of Purified Neural Cell Populations and In Vivo Analysis

Animal studies were approved by the Institutional Animal Care and Use Committee at McLean Hospital and Harvard Medical School. Naïve and unilaterally 6-hydroxydopamine-lesioned adult female Sprague-Dawley rats (200-250 g) were purchased from Taconic (Germantown, NY, http://www.taconic.com). After FACS purification (see above), differentiated hES cells were counted and resuspended at ∼25,000 viable cells per μl in the final differentiation medium. For each surgery, animals were deeply anesthetized with ketamine and xylazine (60 and 3 mg/kg, respectively, i.m.). Injections were performed as previously described [30]. Two to four μl were slowly injected into striatum of the rats (anterior-posterior = 0; lateral = –2.8 from bregma and from –5.5 to –4.5 mm ventral from dura, with the tooth bar set at –3.3). For analysis at five weeks, naïve animals received NS, NC, and ND cell suspensions in bilateral grafts (eight per group). In addition, eight lesioned rats unilaterally received ND cell suspension to be analyzed at 10 weeks post-transplantation. Rats were immunosuppressed with cyclosporin A (15 mg/kg per day; Sandimmune; Sandoz, East Hannover, NJ, http://www.sandoz.com) starting 1 day prior to surgery. Five and/or ten weeks after transplantation, animals were terminally anesthetized by an intraperitoneal overdose of pentobarbital (150 mg/kg) and perfused intracardially with 70 ml of heparinized saline (0.1% heparin in 0.9% saline) followed by 100 ml of paraformaldehyde (4% in phosphate-buffered saline). Brains were removed, postfixed for 4 hours in 4% paraformaldehyde, equilibrated in sucrose (20% in PBS), and sectioned on a freezing microtome in 40-μm slices that were serially collected and stored in cryoprotectant. Two full series of sections were processed for visualization of the respective antigens using immunofluorescence staining, as described above. To identify human cells in the rodent brain, we used the human-specific antibody against human nuclear antigen (1:50; Chemicon/Millipore, Billerica, MA, http://www.millipore.com) and immunohistochemical characterization for human/primate NCAM (Eric-1; Santa Cruz Biotechnology Inc., Santa Cruz, CA, http://www.scbt.com) and human/primate Nestin (Neuromics, Edina, MN, http://www.neuromics.com). The sections were permeabilized with 0.1% Triton X-100 and incubated with primary antibodies in 2% normal donkey serum overnight at 4°C. After rinsing, sections were incubated with appropriate fluorescence-labeled secondary antibodies (Alexafluor; Molecular Probes/Invitrogen, Carlsbad, CA; 1:500) for 1 hour at room temperature, rinsed, and incubated with Hoechst 33,342 (5 μg/ml). Sections were mounted onto Superfrost Plus glass slides (Fisher Scientific, Pittsburgh, PA, http://www.fisherscientific.com), and confocal analysis was performed using a Zeiss LSM510/Meta station. For identification of signal colocalization within a cell, optical sections were kept to a minimal thickness, and orthogonal reconstructions were analyzed. Design-based stereology was performed on the specimens using an integrated bright-field microscope (Axioskop 2; Carl Zeiss, Thornwood, NY), confocal microscope (LSM510), and StereoInvestigator image-capture equipment and software (MicroBrightField, Williston, VT). Graft volumes and ki-67-positive cell counts were calculated using the Cavalieri estimator and optical fractionator probes, from one-sixth of the total sections. The coefficient of error was used to assess probe accuracy, and p < .05 was considered acceptable. The 3D reconstruction was created from one-sixth of the total sections using Neurolucida solid modeling software (MicroBrightField). The graft constituent cell ratios were calculated by blinded investigators counting cells in several [20–30] randomly selected high power fields.

Statistical Analysis

The data were analyzed using a one-way analysis of variance and Tukey-Kramer multiple comparisons test or a two-tailed Student t-test, where appropriate (InStat; GraphPad, San Diego, CA, http://www.graphpad.com; JMP, Cary, NC, http://www.jmp.com). Calculated comparisons of p < .05 were considered significantly different. All reported values represent the mean ± SEM.

RESULTS

Identification and prospective isolation of specific cell subsets using novel markers would enable more detailed studies of neural lineage specification (Fig. 1A). We found that the nestin-positive population contained additional subpopulations that were only detected by analysis for differential expression of surface antigens (Fig. 1B). Distinct levels of CD15, FORSE-1, CD24, CD29, and CD56 antigens underlined the heterogeneity of neuronal differentiation of hES cells (Fig. 1C). Presence of these surface markers was also documented on a number of different neural cell types, including human ES cell-derived neurons and neuroblastoma cells, and varied depending on the time in vitro and/or stage of differentiation (supporting information Fig. 1A, 1B). We therefore investigated whether combinatorial analysis for these markers could yield specific expression patterns (codes) in the developing neural lineage.

Given the rising expression levels of the sialoglycoprotein CD24 (heat-stable antigen; nectadrin; small-cell lung carcinoma cluster four antigen; BA-1) during in vitro development from ES toward the neuronal differentiation (ND) stage (see supporting information Fig. 1A, 1B), this antigen was singled out as a potential marker for the prospective enrichment of differentiated neurons. Already at early stages of neural differentiation (div 14; NP), CD24 expression was observed as evident by utilizing a Sox1-GFP reporter mouse ES cell line [19] (Fig. 2 A, left panel; supporting information Fig. 2A). Presence of CD24 expression on mature neuronal cells types was determined by using transgenic mouse knock-in ES cell-derived Pitx3-GFP+ dopamine neurons [27] as an indicator of late differentiation in ES cell cultures (Fig. 2A, right panel). On human neural cultures derived from hES cells, bivariate FACS analysis identified CD24HI cells to be negative for early neural markers such as the FORSE1, CD15, and CD146 antigens (Fig. 2B). Furthermore, CD24HI cells were also found to be negative for CD133 (data not shown), a marker previously shown to represent a subset of CD15+ cells in hES neural differentiation [15], and did not costain with Pax 3, a neural crest marker (supporting information Fig. 2D). In vitro maturation of hES neural differentiation culture was paralleled by increased CD24HI surface antigen expression (see supporting information Fig. 2B–2D). Cell sorting of human ES cell-derived neural cell suspensions enabled the isolation of CD24HI and CD24LO subpopulations. Post-FACS cell cultures of the CD24HI population were found to be enriched for neurons (Fig. 2C, upper row) and contained less proliferative ki67+ cells than the CD24LO fraction (Fig. 2C, lower row). We also found that, using primary mouse brain cell preparations (E13), the neuronal fraction was enriched by selecting for CD24HI expression (Fig. 2C, supporting information Fig. 2E). CD24HI cultures displayed extension of neuronal processes, forming a dense network immunoreactive for neuronal markers such as Tuj1, MAP2, and synapsin. Viability of CD24HI-purified embryonic fore- and midbrain neuronal cultures was virtually unaffected by the sorting procedure (supporting information Fig. 2F). The CD24LO fraction enriched from hES neural differentiation expressed more Pax6 (14.1-fold enriched; 12.7 ± 0.5 versus 0.9 ± 0.0% in CD24HI), Vimentin (2.6-fold enriched; 6.8 ± 0.4 versus 2.6 ± 0.4% in CD24HI) and Nestin (2.7-fold enriched; 36.1 ± 1.1 versus 13.3 ± 2.0% in CD24HI), all markers characteristic of immature neural phenotype (Fig. 2F, left panel). In contrast, the CD24HI cells were strongly positive for central nervous system (CNS) neuroblast (doublecortin; 13.6-fold enriched; 43.4 ± 1.0 versus 3.2 ± 0.1% in CD24LO) and neuronal markers (TuJ1; 12.8-fold enriched; 46.0 ± 0.5 versus 3.6 ± 0.1%, Tau; 6.7-fold enriched; 32.8 ± 3.0 versus 5.0 ± 0.8% in CD24LO) (Fig. 2F, right panel). Our preliminary conclusion was that CD24HI surface antigen was a marker well correlated with the differentiation of neuronal cells.

Figure 2.

Qualitative analysis of CD24 as a marker for neuronal differentiation. (A) In mouse embryonic stem (ES) cell differentiation, an increase in CD24 surface antigen expression levels was concurrent with the upregulation of neural markers, such as Sox1-GFP (left panel). Sox1-GFP-negative cells did not express CD24 (<0.5%; upper left quadrant). Also, differentiated post-mitotic neurons, here exemplified by the marker for mature dopamine neurons Pitx3-GFP, were characterized to be a subset of the CD24HI population (right panel). 100% of distinctly Pitx3-GFP-positive mES cell-derived neurons showed CD24HI expression (upper right quadrant). Vertical dashed lines (gray) indicate negative versus HI and LO populations of surface marker staining. (B) In human ES-derived cultures at neuronal differentiation stage, CD24HI cells were negative for putative neural precursor or stem cell markers, such as FORSE-1, CD15, and CD146, indicating that CD24 was differentially expressed on differentiating versus proliferative neural cell populations. (C) Qualitative immunocytochemical analysis of neural hES cultures (div 40-45) after sorting according to levels of CD24 surface expression. Post-sort CD24HI cultures (upper row) were found to contain more differentiated neurons (FACS reanalysis and phase contrast images). Plated at identical densities post-FACS, the CD24HI population displayed lower cell numbers overall (Hoechst) and appeared less proliferative (ki67 immunofluorescence) than the CD24LO fraction (lower row). In analogy, using mouse primary midbrain cultures (far right panels), neuronal cells were enriched by selecting for CD24HI. (D) Using conditions optimized for isolation of differentiated neurons [15], CD24HI cultures post-FACS were viable and exhibited signs of further neuronal differentiation and maturation, forming a network of neuronal processes stained with neuronal markers such as βIII tubulin and microtubule-associated protein MAP2 (E). (F) Relative expression of established markers of neural differentiation on CD24LO versus CD24HI populations was detected by bivariate flow cytometric analysis for intracellular antigens on CD24 labeled cell suspensions (see supporting information data). CD24LO cells were strongly positive for the neuroepithelial marker Pax6 and also for the intermediate filament and precursor cell markers vimentin and nestin (left half). In contrast, the neuroblast marker doublecortin and markers of neuronal differentiation, such as TuJ1 or the microtubule-associated neuronal Tau antigen, were predominantly expressed on the CD24HI population (right half of panel F). Data is displayed on a logarithmic scale, showing relative expression of the respective marker on either subset normalized against an unsorted, non-gated control representing the overall population. Scale bars = 50 μm. Abbreviations: DCX = doublecortin; FACS = fluorescence-activated cell sorting; hES ND = human embryonic stem cells at neuronal differentiation stage; mES ND = murine embryonic stem cells at neuronal differentiation stage; mES NP = neurally induced murine embryonic stem cells at the neuroepithelial precursor stage; TuJ1 = βIII tubulin.

In contrast, CD15 (stage-specific embryonic antigen-1, Lewis-X antigen), a more immature marker staining a carbohydrate epitope (fucosyl-N-acetyl-lactosamine), was absent on differentiated neurons, including dopamine neurons identified by Pitx3-GFP expression (Fig. 3A). Known as an established mouse ES cell and a myeloid differentiation marker [34–37], it is important to note its clear and distinct labeling of mouse neuroepithelium, as shown on midbrain sections of E13 mouse embryos (Fig. 3B). In human ES cell differentiation, CD15 was found to be strongly expressed on Sox1 and Sox2-positive neuroepithelial rosette structures (Fig. 3C). CD15 expression was thus determined to be a marker of immature, neuroepithelial cells, enabling their enrichment, or alternatively their depletion, for applications in developmental as well as cell therapeutic paradigms.

Figure 3.

Qualitative analysis of CD15 and CD29 surface antigens on proliferative neural subpopulations. (A) In mouse ES cell differentiation, CD15 expression is absent on neuronally differentiated subsets, as exemplified by absence on Pitx3-GFP-expressing differentiated dopamine neurons (>98% of Pitx3-GFP positive cells were negative for CD15; upper left quadrant). In addition to being a known marker for immature mouse (but not human) ES cells, enabling the elimination of this unwanted subset in neural transplantation paradigms [6], CD15 is also present on neuroepithelial cells in the developing mouse embryo (E13 midbrain section; B). Asterisk indicates lumen of neural tube; arrowheads indicate non-neuroepithelial cells are not immunoreactive for CD15. Scale bar = 100 μm. (C) In the context of human ES cell neural differentiation, CD15 surface antigen specifically labeled neuroepithelial cells forming typical rosette-like structures (*). CD15 expression co-localized with the neural precursor marker Sox1 (left panel), the neural stem cell marker Sox2, and also the early neuroepithelial marker Pax6 (not shown), and its expression was restricted to such rosette clusters (dashed outline). More differentiated cell types in proximity to such proliferative neuroepithelial clusters displayed low/no expression of the CD15 antigen (arrowheads). Scale bar = 50 μm. (D) Similarly, the CD29 antigen was present on neuroepithelial cells, co-staining for Pax6 and also Sox2 (not shown). Differentiating neuroblasts emerging from these highly proliferative clusters were negative/low in CD29 expression (DCX expression in blue; left and mid-lower panel). In addition, CD29 expression was strongly present on a population of mesenchyme-like proliferative cells, migrating away from neural rosette cultures (right lower panel). This subset did not costain with markers of central nervous system-neuronal fate specification such as doublecortin. Scale bars = 50 μm. (E) FACS analysis enabled the analysis and separation of these newly identified subsets (upper panels). Upon sorting, the CD29LO population was enriched for cells of neuronal phenotype (left lower panel), while the CD29HI fraction mainly contained proliferative stem cell-like clusters (arrow) and proliferative “flat” mesenchyme-like cell types without epithelial polarization or neuronal differentiation (arrowheads; right lower panel). Scale bars = 50 μm. Abbreviations: DCX = doublecortin; FACS = fluorescence-activated cell sorting; hES ND = human embryonic stem cells at neuronal differentiation stage; mES ND = murine embryonic stem cells at neuronal differentiation stage.

Similarly, the CD29 antigen (beta1-integrin) was found to predominantly label the neuroepithelial rosette structures typical of hES neural induction (Fig. 3D). CD29 expression decreased from 81.3 ± 6.8% at rosette stage (div 21) to 53.6 ± 4.7% at differentiation (div 42; three independent experiments; not shown). At those later stages of in vitro neural differentiation, remaining clusters of proliferative neural stem cells displayed enhanced expression of CD29 (supporting information Fig. 3A). Doublecortin-positive neuroblasts emerged from such more immature clusters and were negative for CD15 and also CD29 expression (Fig. 3D). Interestingly, a second population of mesenchyme-like proliferative cells, typically forming a halo around dense neuroepithelial cell groups, was identified to also strongly express CD29 (Fig. 3D; supporting information Fig. 3B). Upon FACS analysis and cell sorting experiments, the CD29HI fraction was enriched for proliferative spherical clusters as well as proliferative adherent cell types (Fig. 3E). In contrast, the CD29LO enriched fraction contained predominantly process-bearing post-mitotic neurons (Fig. 3E). CD29HI contained more nestin (41.5%) and less TuJ1 (25.3 ± 0.5%), CD29LO showed reduced nestin (9.6%) and increased TuJ1 (65.6 ± 1.1%); TuJ1 in this subset is determined by flow cytometric analysis of intracellular neural antigens (single experiment) (supporting information Fig. 3C, 3D). Consistent with those observations, the CD29LO fraction was also enriched for doublecortin-positive cells (50.2 ± 14 compared to 9.5 ± 3.5 in the CD29HI population; three independent experiments; supporting information Fig. 3E).

Our findings thus far suggested that the fraction of neurons was augmented by sorting for CD24HI-expressing cells, as well as for CD15 or CD29LO-expressing cells. In contrast, more proliferative cell populations were enriched by isolating the CD24LO, the CD15+, and/or the CD29HI cell subsets (see Figs. 1–3). In order to fully characterize specific neural subpopulations according to surface antigens, combinatorial FACS analysis for the above and a variety of complimentary surface markers [15] was performed (Fig. 4A): (i) CD29LO cells were found to also exhibit CD24HI and CD56HI, a surface antigen pattern consistent with differentiation towards neuroblasts and neurons [15, 38]. (ii) Precursor or stem cell markers, such as CD146 [15], FORSE1 [39] or CD15 [15] (Fig. 3), CD133 [40], respectively, were present on the CD29MID/HI subset. (iii) Finally, CD29HI cells were found to express surface antigens consistent with mesenchymal and/or neural crest phenotypes, such as CD271, CD57, and CD73 [41] (Fig. 3). Key populations of neural lineage development were hereby defined according to a CD15/CD24/CD29 surface antigen code, as depicted in Figure 4B, 4C. A CD15+/CD24LO/CD29HI surface antigen profile defined presumptive neural stem/progenitor cells (NS). In contrast, CD15/CD24LO/CD29HI expression was characteristic of a presumptive neural crest/mesenchymal cell population (NC). Finally, a CD15/CD24HI/CD29LO surface antigen signature defined a presumptive neuronal/neuroblast population (ND). The temporal dynamics of CD15/CD24/CD29 surface expressions in vitro were consistent with NS, NC, and ND phenotypes (supporting information Fig. 4B, 4C): at later stages of in vitro maturation, a shift toward ND population was observed. However, also at prolonged differentiation in culture (up to 70 div analyzed), all three populations remained present (data not shown). Ki67+ cells appeared enriched in the NS population, whereas the central nervous system precursor marker doublecortin and the neuronal microtubule-associated protein (MAP)-2 were highly expressed in the ND population (supporting information Fig. 4A). We then used cell sorting experiments to isolate these subsets from typical heterogeneous cell populations differentiated from hES cells (H7 and H9; div 35-42) and found them to be morphologically clearly distinct (Fig. 4C). The CD15+/CD24LO/CD29HI subset (NS) was enriched for proliferative clusters, giving rise to neural precursor/neurosphere cultures (Fig. 4D). The CD15/CD24LO/CD29HI subset (NC) presented with massive proliferation of flat, adherent cells after cell sorting. In contrast, the CD15/CD24HI/CD29LO subset (ND) represented a purified culture of cells with neuronal morphology (Fig. 4D).

Figure 4.

Deciphering a surface antigen code of neural lineage differentiation. (A) Combinatorial staining for CD29 with various other surface antigens suggested the presence of distinct cell subsets. Proliferative hES cell-derived neural cell cultures (div 35-42) displayed a characteristic pattern of CD29 expression. The CD29LO fraction (green label; second column) included cell populations positive for CD56 (NCAM) and for the CD24 antigen (expressed on neuronal cell populations; Fig. 2). The CD29HI population contained a subset (blue label; right column) that co-labeled with CD271 (p75) and CD73 antigens, markers known to be present on mesenchymal and neural crest cell derivatives [41, 65]. An additional CD29HI subset (red label; fourth column) included populations that co-stain CD15 (shown to be characteristic for neuroepithelial cells; Fig. 3), FORSE-1, and CD133 (Prominin-1) [15, 66]. Intermediate stages of differentiation could be inferred by detecting a transient distinct population of CD29MID cells (yellow label, mid column), which colabel with FORSE-1 and CD146, markers recently described to be present on proliferative neural cell types [15, 39]. These markers did partially overlap with the neuroepithelial stem cell fraction (red) with respect to CD29 expression. Left column: CD29 without co-staining for additional antigens. (B) Thus, a CD15+/CD29HI population was identified, labeled in red (upper panel), which also displayed low CD24 expression, as depicted in the lower panel (red outline). In summary, this subset of neuroepithelial/neural stem cells (NS) was hypothetically characterized by CD15/CD24HI/CD29LO surface antigen expression. Analogously, an additional subset negative for CD15, but showing CD29HI and CD24LO expression, was determined (CD15/CD24LO/CD29HI; blue outline), potentially representing a mesenchymal or neural crest-like (NC) population, given its co-labeling with markers of such phenotype as shown in (A). Finally, a neuronally differentiating/ neuroblast (ND) neural subset was inferred to be characterized by the distinct surface antigen code CD15/CD24HI/CD29LO (green outline). (C) Combinatorial FACS analysis according to the CD15/CD24/CD29 surface antigen code enabled the enrichment of specific neural cell populations differentiated from a mixed neural population derived from human pluripotent stem cells. The upper row displays the presumptive neuroepithelial/neural stem cell (NS) subset. Upon sorting (FACS reanalysis, left column), this subset shows enrichment for proliferative clusters containing neuroepithelial stem cells (phase contrast images; right columns). Selecting the CD15/ CD24LO/ CD29HI fraction (second row) enriched for highly proliferative “flat”, migratory cell types. The CD15/ CD24HI/ CD29LO subset (lower row) displayed cultures devoid of the previous cell populations and presented with a network of processes from neuronally differentiating cell types in high purity (D). Scale bars ≈ 50 μm. See Methods for sorting parameters optimized for neuronal cell sorting and post-FACS culture conditions. Abbreviations: hES ND = human embryonic stem cells at neuronal differentiation stage; NS = CD15+/CD24LO/CD29HI; NC = CD15/CD24LO/CD29HI.

Subsequent detailed in vitro analysis of the neural cell populations identified according to CD15/CD24/CD29 expression codes confirmed the prospective isolation of distinct subsets consistent with phenotypes of neural stem/progenitor (NS), neural crest/mesenchymal (NC), and neuronal/neuroblast (ND) cells, respectively (Fig. 5; supporting information Figs. 2D; 3B, 3C; 4A–4C). Quantitative analysis of gene expression revealed characteristic expression patterns for the isolated subsets, with ND cells predominantly expressing βIII-tubulin (2.8-fold increased expression over NS, 6.3-fold increase over NC population; qRT-PCR; Fig. 5A). Investigations on the protein level mirrored this expression pattern, characterizing ND cells as the fraction with the highest presence of βIII-tubulin (Fig. 5B). Sorting for CD15/CD24HI/CD29LO (ND) enabled the isolation of viable postmitotic near-pure neuronal cultures. Under high-purity sorting conditions, those cultures were devoid of ki67+ cells (Fig. 5C). Sphere formation assays underlined this reduced proliferative capacity of the ND (no spheres) versus the other populations (0.6 ± 0.2 and 3.2 ± 1.5 spheres per well in the NS and NC populations, respectively; supporting information Fig. 4E). We then tested the CD15/CD24/CD29 neural surface antigen code combination for its applicability as a marker set enabling the prospective isolation of specific neural subpopulations in transplantation experiments, for both therapeutic and basic developmental studies (Fig. 5D–5H). The three described populations (NS, NC, ND) were isolated from differentiated human ES cell cultures (H9; div 42) by FACS and subsequently grafted into rodent brain for histological analysis after 5 and 10 weeks post-transplantation. Consistent with the emerging hypothesis and designation of the combinatorial code (see above; Fig. 4B, 4C), grafts from the CD15+/CD24LO/CD29HI (NS) group showed neuroepithelial tumors, which displayed characteristic neural rosettes exhibiting immunoreactivity for Sox2, Nestin, Vimentin, and radial glial markers 3CB2, RC2 (Fig. 5D, 5E; and data not shown) (n = 8 grafts). The CD15/CD24LO/CD29HI group (NC) showed similarly debilitating tumor formation of more diffuse composition with a strong component of migratory, mesenchyme-like cells. Confirming its characterization as neural crest/mesenchymal phenotypes, cells in these grafts were strongly CD271 positive (Fig. 5D; n = 8 grafts). Myosin-positive muscle cells in the host brain, a confounding component of neural grafts in previous studies [7, 9, 16], were exclusively found in this group (Fig. 5E). In contrast, CD15/CD24HI/CD29LO (ND) grafts were composed of human-NCAM-positive cells, extending neuronal processes into the host brain tissue (Fig. 5F). Ki67-positivity in the graft area was decreased in the ND group (NS: 55.7 ± 21.4; NC: 54.3 ± 20.4; ND: 2.6 ± 1.0; 1.3 ± 1.0; 1.0 ± 0.2 × 103; supporting information Fig. 4D, 4E). No tumor formation was observed at either 5 (two independent groups, n = 5 each) or 10 weeks (n = 8 grafts). Graft volume in the ND groups ranged between 4.8 and 20.9% compared to that observed in the NS and NC groups; Fig. 5G, 5H). Graft analysis clearly demonstrated that the prospective isolation of specific neural subsets according to CD15/CD24/CD29 surface antigen expression resulted in distinct graft composition and characteristics. Being important from a therapeutic perspective, the CD15/CD24HI/CD29LO (ND) group exclusively comprised neuronal grafts without tumor formation.

Figure 5.

Analysis of human ES cell-derived neural subpopulations identified according to CD15, CD24, CD29 expression. (A) mRNA expression of Sox1 and βIII-tubulin. The CD15/CD24HI/CD29LO population (ND) showed strong presence of the neuronal differentiation marker βIII-tubulin (50 kDa), confirmed by Western blot (B). (C) High-purity cell sorting of this subset enabled the derivation of viable, pure neuronal cultures (reanalysis: > 95%), in which clusters of proliferative stem cells or non-neuronal cell types were absent. Inset = higher magnification. (D) Upon transplantation into rat brain (striatum), progeny of either population exhibited distinct developmental potential, as detected by histological analysis of the respective grafts after 5 weeks in vivo. (i) NS grafts (CD15+/CD24LO/CD29HI) showed formation of neuroepithelial tumors. (ii) NC grafts (CD15/CD24LO/CD29HI) did not show any/few neuroepithelial rosette structures but presented tumors with massive presence of proliferative, strongly CD271 (p75)-positive cell types. (iii) ND grafts (CD15/CD24HI/CD29LO) did not show tumor formation but presented with confined neuronal grafts, staining positive for human neural markers (Fig. 5F; supporting information Fig. 4D). Note that hES-derived neural cell suspensions were FACS-enriched for NS, NC, and ND cell populations to ∼80% purity prior to transplantation. Pseudocolor images were obtained with identical setting for each experimental group using confocal microscopy. Scale bars = 200 μm. (E) Neural tumors (NS group) were composed of typical neuroepithelial rosette-like structures and doublecortin (DCX)-positive neuroblasts emerging from the former (upper panel). Myosin-positive cells were exclusively found in the NC grafts, underlining that the surface antigen combination of CD15/CD24LO/CD29HI enabled the prospective selection of neural crest/mesenchymal cells types using the neural surface antigen code. Scale bars = 50 μm. (F) In contrast, the ND group presented with tumor-free neural grafts, extending neuronal processes into the host brain tissue. Dashed line ≈ graft outline. Scale bar = 50 μm. (G) Graft volume analysis documented that tumor formation was attenuated by FACS for CD15/CD24HI/CD29LO. (H) Proliferative ki67-positive cells were greatly reduced in the CD15/ CD24HI/ CD29LO grafts. A further reduction in proliferative cells was observed from five weeks compared to ten weeks after transplantation (far right column, 10 wks; n = 8). Error bars indicate standard error. (I) Schematic of CD15, CD24, and CD29 expression dynamics during neural lineage differentiation. A population characterized by high levels of CD15 and CD29 (NS, red) may develop towards two distinct subsets: one losing the CD15 expression while maintaining the CD29 expression (NC, blue), another one decreasing both CD15 and CD29 expression and gaining surface expression of CD24 (ND, green). Abbreviations: DCX = doublecortin; NS = CD15+/CD24LO/CD29HI; NC = CD15/CD24LO/CD29HI; ND = CD15/CD24HI/CD29LO group.

DISCUSSION

These experiments demonstrate that different combinations of the CD15, CD24, and CD29 surface antigens define distinct cellular subsets of neural lineage differentiation, including bona fide neural stem, neural crest/mesenchymal cells, and neuronal cells from human pluripotent stem cell cultures. We observed these biomarkers consistently on a variety of neural cell types and propose a model for selecting developing neural cells based on these distinct profiles (Fig. 5I; Table 1). Cell sorting using these neural surface antigen codes enabled the selection of specific cellular subsets from heterogeneous neural cell populations. After transplantation, the CD15/CD24HI/CD29LO cell population yielded near-pure neuronal grafts, while the other subsets formed large neuroepithelial (CD15+/CD24LO/CD29HI) or neural crest/mesenchymal (CD15/CD24LO/CD29HI) tissue tumors.

Table 1. Schematic surface antigen profile of the NS, NC, and ND populations identified and defined by CD15, CD24, and CD29 expression code
inline image

CD15 (Lewis-X antigen, SSEA-1), and also CD133 (Prominin-1), have previously been identified as putative markers of stem cell identity not only in the neural system [15, 22, 42, 43] but also in hematopoietic [44, 45] and other [36, 46–48] cell types, suggesting functional relevance for “stemness” properties in general, for example for adherence to stem cell niches [49]. While CD15 and also the structurally related FORSE-1 antigen are strongly expressed on neuroepithelial cells, they are both downregulated upon further differentiation, which suggests that delamination from the neuroepithelial tube/rosette-like structures parallels surface expression changes of these glycolipid markers [50]. This is consistent with the observation that CD15 is present on neural stem cells in vivo, residing in stem cell niches of the adult brain [51], including the recent identification of CD15 on nervous system tumor cells, such as medulloblastoma [52, 53]. Similarly, integrins play an important role in neural development [54], and CD29 specifically was observed on human neural stem cells obtained from fetal tissue [55]. In addition, integrin signaling has been shown to be of functional relevance for both neural crest [56] and mesenchymal development [57, 58]. The distinct pattern of CD29 expression suggests that β1-integrin signaling, and regulatory events affecting cell adhesion, are of functional relevance in neural development not only in vivo but also in artificial in vitro systems. Again, analogous to physiological development in vivo, delamination of neural cells from neuroepithelium/neural tube-like structures can be observed [59], with differentiation toward neural crest/mesenchymal versus CNS neuronal phenotypes (see Fig. 3 D). In contrast, CD24 was identified to be upregulated with neural differentiation and neuronal maturation. We demonstrate that its surface expression is well correlated with known markers of differentiating neurons, such as Pitx3, TuJ1, and MAP2, and that high levels of CD24 surface expression are a valid marker for maturing neuronal cell types in in vitro neural differentiation (Table 1). Consistent with our findings, Uchida et al. have described only low levels of CD24 on human neural stem cells isolated from human brain [22], and Rougon et al. showed that CD24 labels neuroblasts in neurogenic niches of mouse brain and during development [60]. Here, FACS for CD24HI was introduced to isolate purified neuronal cultures from primary rodent embryonic brain tissue, which provides a valuable tool to analyze pure neuronal subpopulations under defined conditions. In hES cell cultures, we observed that a separation into a CD24LO versus a CD24HI population occurred with the transition from a mixed neural precursor cell population to the neuronal differentiation stage (see supporting information Fig. 2). Yet, given the population dynamics in the dish [15] and the promiscuity of surface markers [61], a flow cytometric gating strategy according to a single marker would be insufficient to isolate a pure, neuronally differentiating population from heterogeneous stem cell cultures. Characterizing the CD15/CD24/CD29-defined populations for coexpression of additional neural surface markers may enable future studies on the relevance of these dynamic changes during in vitro neuropoiesis (see Fig. 4A). The presence of CD15/CD24/CD29 antigens on various neural cell types including mouse embryonic primary mid- and forebrain, spinal cord and stromal tissue, as well as ES and iPS cells, suggests more general applicability of this code (see supporting information Fig. 1B) not only for neurodevelopmental studies and cell therapeutic paradigms but potentially also in the diagnosis and study of neural tumors [62]. It remains to be seen to which extent the dynamics of CD15, CD24, CD29 expression on these other cell types mirror the code described here for human neural cells derived from ES cells: the NS population, characterized as CD15+/CD24LO/CD29HI, comprises a CD133 population and positivity for FORSE-1, nestin, Pax6, Sox1. It generates proliferative neural clusters and spheres in vitro, and leads to the formation of rosette-containing neuroepithelial tumors reminiscent of medulloblastoma. We do not formally study the generation of NC from NS cells, but sorting for CD15 appears to generate neurosphere-like cultures that, in turn, are able to give rise to heterogeneous cultures of NS, NC, and ND populations (Fig. 5I). The precise level of multipotency of this overall population versus its subsets demands to be further elucidated [63], but all of the above features are consistent with neural stem cell character (see summary, Table 1). It will be clinically important to control and limit the presence of this proliferative population from a grafted cell suspension. In addition, the combinatorial code used here may serve to expand the biomarker library used to isolate neural stem cells from cell cultures as well as from primary tissue.

The NC population (CD15/CD24LO/CD29HI) entails subsets expressing Pax3, CD57 (HNK1), and CD271 (p75), all of which have been described on neural crest cells [64, 41, 59]. Furthermore, it contains markers also present on mesenchymal derivatives, including CD271, CD73 (ecto-5-nucleotidase), and myosin [65, 58] (Table 1). Further analysis will be required to determine in which way neural crest derivatives such as peripheral neuron cells and melanocytes differentiate from this newly defined hES subset, and whether the mesenchymal cells are in fact generated via cranial neural crest-like cells in culture, or via mesodermal specification from the original pluripotent source [58]. From our current focus on cell transplantation to models of neurodegenerative disease in the CNS, it is an important finding that excluding this population is a prerequisite for tumor elimination and enhances the purity of the graft, as evidenced by absence of myosin-positive cells.

Finally, the ND (CD15/CD29LO/CD24HI) population was found to provide tumor-free neuronal grafts. In vitro, virtually pure neuronal cultures were established by sorting for this surface antigen combination. Markers co-expressed in this population include neuroblast and neuronal markers doublecortin, TuJ1, and MAP2, while more immature markers such as Pax6 and FORSE-1, the formation of proliferative clusters, are absent. While this study addresses one major obstacle to neural stem cell therapy, i.e. the formation of tumors, the derivation and stability of functional therapeutic phenotypes are still a challenge that needs to be solved. A better understanding of the cell populations present in culture and their interactions in the dish may contribute to achieving that.

SUMMARY AND CONCLUSION

In summary, these data provide a novel surface antigen code for neural lineage differentiation. Dynamic changes in surface expression of the identified antigens CD15, CD24, and CD29 in combination (Table 1) can be exploited for the experimental separation of key neural cell populations derived from developing human stem cells.

Acknowledgements

We thank Shreeya Karki and Casper Reske-Nielsen for excellent technical assistance. This work was supported by a National Institutes of Health grant (P50NS39793), the Michael Stern Foundation, the Orchard Foundation, the Consolidated Anti-Aging Foundation, and the Harold and Ronna Cooper Family.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

The authors indicate no potential conflicts of interest.

Ancillary